Abstract
e24067Background: Advanced gastric cancers are usually not curable conditions for which systemic treatments are indicated. Recent studies suggest that circulating free plasma DNA of tumoral origin ...
Highlights
Advanced gastric cancers are usually associated with incurable conditions for which systemic treatments are indicated
The majority of Gastric cancer (GC) patients in the United States are symptomatic at diagnosis, and they already present with locally advanced disease that is unresectable or metastatic at the initial manifestation
Because most patients are diagnosed with advancedstage GC, they require treatment based on palliative chemotherapy, and the goal is to increase quality of life and overall survival
Summary
Advanced gastric cancers are usually associated with incurable conditions for which systemic treatments are indicated. Recent studies suggest that circulating cell-free plasma DNA of tumour origin (tDNA) is a promising non-invasive biomarker that can be used to predict the prognosis and monitor the efficacy of systemic treatments in patients with certain types of cancer. We conducted a pilot study to analyse the potential role of tDNA as a biomarker in patients with advanced gastric cancer. Because most patients are diagnosed with advancedstage GC, they require treatment based on palliative chemotherapy, and the goal is to increase quality of life and overall survival. In this context, to monitor the response to treatment, computed tomography (CT) is currently the primary tool used in the diagnosis and clinical management of GC. Peritoneal dissemination is a more frequent pattern of recurrence or progression in GC and is generally difficult to detect by imaging [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
